AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04413968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: Stool collection in children
Study NCT01261624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: 1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
Study NCT04408534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mode of noninvasive ventilation
Description: administration of during 3 hours each 4 cycles
Study NCT04408534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mode of noninvasive ventilation
Description: administration of during 3 hours each 4 cycles
Study NCT01156896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
Study NCT01156896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
Study NCT01156896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
Study NCT01156896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
Study NCT02404857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG based Brain Computer Interface
Description: Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
Study NCT03686215 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Study Device Arm
Description: LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
Study NCT01720849 — intervention group
Intervention type: DRUG
Intervention: Fampyra
Description: The will be given as per normal patient treatment plan
Study NCT03601494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perineural injection of platelet-rich plasma
Description: Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
Study NCT03601494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medical
Description: vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
Study NCT03601494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical
Description: vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
Study NCT00003850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT00869687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Poly-L-Lactic Acid Injection
Description: 0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: 50 mg capsules co-administered with ritonavir
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: 50 mg tablet
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 400 mg tablet
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsules co-administered with ABT-450
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT01074008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT01074008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
Study NCT02359344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Study NCT02359344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04348279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: propylene mesh
Description: propylene mesh as a palatal stent for palatal wound
Study NCT04348279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: propylene mesh
Description: propylene mesh as a palatal stent for palatal wound
Study NCT04470778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study NCT04470778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study NCT02215096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
Study NCT02215096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
Study NCT04634383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WFMA - wireless floating microelectrode array
Description: Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
Study NCT01237938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Diet
Description: Changing to low glycemic diet
Study NCT01904227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard outpatient DBT
Description: Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
Study NCT01904227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Adaptation of DBT
Description: The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study NCT00406718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med-eMonitor
Description: Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
Study NCT00406718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PharmCAT
Description: Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
Study NCT00406718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
Study NCT03078400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL-108
Description: Subcutaneous injection of 150 mg administered either one time or two times per day.
Study NCT00137215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon
Description: dressing for donor site mamagement
Study NCT03521219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study NCT04626024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
Description: Stop taking TKI medication
Study NCT04626024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Description: Re-start TKI medication
Study NCT01231633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Ozurdex, 0.7mg dexamethasone
Study NCT01231633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
Study NCT01231633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
Study NCT03993691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomo-E scan
Description: High-resolution limited-angle tomography positioning and examination will vary depending on injury.
Study NCT03993691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph
Description: Standard of Care radiographic imaging of wrist.
Study NCT02994589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm™(Absorbant, 3M)
Description: 3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
Study NCT02994589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OASIS® wound matrix
Description: OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
Study NCT02994589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform™
Description: Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Interferential Current
Description: Involves the application of medium frequency alternating currents
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Laser
Description: Involves the application of low level laser over the knee
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Interferential Current
Description: It is a sham interferential therapy
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Interferential Current
Description: It is a sham interferential therapy
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Laser
Description: It is a sham laser therapy
Study NCT02898025 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: It is a sham laser therapy
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Atorvastatin
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Study NCT01495013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg Atorvastatin
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Study NCT02602652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a live attenuated chimeric JE vaccine
Description: The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity.
Study NCT02264366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Communication for Health Behavior management
Description: An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006).
Study NCT04873557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper-based surfaces plus copper-enriched linen
Description: We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
Study NCT03448276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the vibrating platform
Description: 20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
Study NCT03448276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walk
Description: Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
Study NCT01550367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
Study NCT01550367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
Study NCT02656316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: In this group subjects will receive 20 min of treatment.
Study NCT02656316 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In this group subjects will receive 20 min of sham stimulation.
Study NCT03395015 — intervention group
Intervention type: OTHER
Intervention: VAS scale (from 1 to 10) esthetic assessment of facial 3-D images
Description: The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
Study NCT01198249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
Study NCT03495206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2(Edaravone And Borneol) Sublingual Tablet
Description: Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
Study NCT03801317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC/ egg
Description: 4.3 egg powder + 5.7 g bovine colostrum
Study NCT03801317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 15 grams corn-soya blend
Study NCT03801317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multiple micronutrient
Description: multiple micronutrient sprinkle powder
Study NCT03801317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multiple micronutrient
Description: multiple micronutrient sprinkle powder
Study NCT00916695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.
Description: Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.
Study NCT00646503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day, oral telbivudine for 52 weeks
Study NCT01367938 — intervention group
Intervention type: DEVICE
Intervention: OMNI Apex Ultracongruent Knee Device
Study NCT03255044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin administered as well as standard heart failure therapy
Study NCT03255044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin administered as well as standard heart failure therapy
Study NCT03255044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline directed therapy
Description: standard heart failure therapy
Study NCT03187587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imILT
Description: The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.